Dr. Von Minckwitz On Pathologic Complete Response In Breast Cancer

Dr. von Minckwitz on Pathologic Complete Response in Breast Cancer

Targeted Oncology

Dr. Gunter von Minckwitz on pCR and Outcomes in Breast Cancer

Predicting pathological complete response in breast cancer

Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer

Dr. von Minckwitz on Non-Responsive Breast Cancer Patients

Utilizing Pathologic Complete Response in Breast Cancer Trials

Dr. Eric P. Winer on Pathologic Complete Response and Disease Free Survival in Breast Cancer

Targeted Oncology

Association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...

The genetics of breast cancer complete response

Dr. von Minckwitz Discusses the Rationale Behind the Phase III PENELOPE Trial

Dr. Burstein Discusses Pathological Complete Response

CompassHER2-pCR: de-escalation of neoadjuvant chemotherapy for breast cancer

Dr. Harry Bear on Translating Pathological Complete Response to OS Benefits

Targeted Oncology

Reducing Risk in Residual Breast Cancer

Changes in tumour biomarkers after neoadjuvant chemotherapy in breast cancer

SABCS 2013: NeoALTTO, breast cancer with pathologic complete response, event-free & overall survival

The predictive value of treatment response after neoadjuvant therapy

Pathological complete remission (pCR) of breast cancer following neoadjuvant chemotherapy (NACT)

Alexandros G. Sfakianakis

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast Cancer

Dr. von Minckwitz on Phase III Results of the APHINITY Trial for Breast Cancer